EARLY DETECTION of tumour metastasis is important for the clinical oncologist, since the therapeutic modalities may be influenced by the tumour stage. For some common tumours the first metastases are often in bone.
The symptoms of skeletal metastasis either appear late or lack specificity. Various biochemical markers have been put forward for the early detection of tumours or their metastases (Coombes et al., 1977) . For skeletal metastases, the isoenzymes of alkaline phosphatase were introduced into the clinical laboratory, but they did not bring the expected diagnostic advantage (Fishman & Ghosh, 1967) .
The collagen metabolite hydroxyproline is released mostly from bone but also from other connective tissue in adults (Laitinen, 1974) . It has raised "particular hope and interest" as a marker of skeletal involvement by tumours (Reynoso, 1973) . This amino acid is fairly specific for bone turnover. It is produced by hydroxylation of proline, previously integrated in the procollagen molecule (Grant & Prockop, 1972) and it is released from bone when the connective tissue is broken down in bone turnover (Klein et al., 1964) .
Several clinical studies have proved the relevance of total urinary hydroxyproline in the diagnosis of various disorders of bone (for review see Laitinen, 1974) and particularly in the diagnosis of skeletal metastasis of various tumours (Basu et al., 1974; Bonadonna et al., 1966; Guzzo et al., 1969; Hosley et al., 1966) . Kontturi et al. (1974) have studied free serum hydroxyproline (FSHP) in prostatic carcinoma. Powles et al. (1975) have shown the value of the total urinary hydroxyproline/ creatinine ratio (HP/CR) for the evaluation of the response to a given treatment in breast cancer metastatic to the skeleton.
We have planned the present study to answer to the following questions: -What is the diagnostic value of FSHP and HP/CR for the detection of skeletal metastasis of breast cancer? We were aware, however, of the relatively low expected incidence of skeletal metastasis in such a prospective trial. The patients were entered into the study within 4 weeks after mastectomy. If postoperative radiotherapy was performed, the interval admitted was less than 16 weeks. After initial examination the patients were randomized between a treatment for 6 months and a treatment for 24 months. Chemotherapy consisted for all patients of oral chlorambucil, methotrexate and 5-fluorouracil. The patients were monitored at least every 3 months with clinical, laboratory and radiological examinations.
The study ended if there was a morphological proof of local recurrence and/or metastasis, either (whenever possible) by histology or cytology, or by unequivocal radiological findings. In respect of skeletal metastasis a pathological bone scan in the absence of a clearcut radiological change was considered insufficient reason for withdrawing the patient from the study.
The collection of samples for hydroxyproline started in the spring of 1976 and ended in December 1979. The patients continued to be followed as previously.
We have divided the patients into 5 groups: I: With no local or distant recurrence until 1 year after the last hydroxyproline sample.
II: The same criteria as Group I, but the patients received no chemotherapy, since they were taken from a parallel study with similar criteria but with a control arm (OSAKO study).
III: With skeletal metastasis. I V: With liver metastasis. V: With local recurrence or with metastasis elsewhere than liver or bone.
For the determination of FSHP and HP/CR, serum and urine were taken after an overnight fast and a diet excluding all collagen for 24 h. Blood was separated immediately and the serum was frozen. The chemical methods are detailed elsewhere (Gasser et al., 1979) .
Urinary total HP was measured and expressed as its ratio to creatinine (CR) (mM x 100/mM). The In order to test the predictive value of the above measurements, we arranged the individual results according to the appearance of recurrence at 3 monthly intervals. For the control groups (I and II), we have arbitrarily chosen a point of zero time, for which there is a minimal further follow-up of 1 year with no sign of recurrence. We have excluded patients without at least 3 consecutive values during the observation period.
A classical analysis of variance (Snedecor & Cochran, 1967 ) and a nonparametric analysis (Urquhart et al., 1973) were performed. Finally, the 4 following comparisons were calculated according to Kruskal (1952) (Group V) found in 27 patients during the observation period. Ages and details of menopausal status are presented in the Table. The Figure There is only one significant difference for FSHP: between Groups I and II at 0-3 months (P=0.018). For HP/CR there are 2 significant differences at 0-3 months:
between Groups III and IV (P = 0.007) and between III and all the other patients (P < 0-001). This latter difference exists also at 6-9 months (P=0 01). Another highly significant difference exists for alkaline phosphatase at 0-3 months, between Groups III and IV (with skeletal and hepatic metastases) and all the other groups (P = 0 001).
The present prospective study of 2 collagen metabolites (FSHP and HP/CR) was designed for testing their value for the detection of bone metastasis. (Gasser et al., 1979) . In our present study, there was only one value outside the normal range. HP/CR has been shown to be useful in evaluating the response of malignant disease with bone involvement to treatment (Powles et al., 1975) . Its sensitivity has been estimated at between 720% (Coombes et al., 1977) and 92-4% (Bonadonna et al., 1966) .
If we compare the pooled values of HP/CR for the groups without metastasis with the reference values of our laboratory, the former are clearly higher. We have no explanation for this difference. Our reference values are concordant with those of others, and there are no differences for sex or age between 25 and 70 years (Laitinen, 1974) . A relationship to breast cancer or the surgical procedure seems highly improbable. Dietary intake of collagen barely influences the measurement of HP/CR (Gasser et al., 1979; Posma et al., 1981 
